Biomarker analyses on tumor tissue and liquid biopsy are ongoing and will be of utmost relevance, given the possibility to compare treatment naïve baseline samples with samples collected at the time of interval debulking surgery, following exposure to ICIs, and the possibility to explore possible correlations between BRCA and homologous recombination deficient (HRD) status, tumor mutational burden (TMB), PD-L1 expression and immune signatures [43]. The gene discussed is CD274; the disease is neoplasm.